Nothing said here yet.
to join the conversation.
| Crotty Dylan BramGroup President | Sell | 441 | $144.9K | Fri, Aug 21 |
| STRYKER RONDA EDirector | Sell | 16,612 | $5.7M | Wed, Aug 19 |
| STRYKER RONDA EDirector | Sell | 11,257 | $3.8M | Wed, Aug 19 |
| STRYKER RONDA EDirector | Sell | 10,812 | $3.7M | Wed, Aug 19 |
| STRYKER RONDA EDirector | Sell | 3,852 | $1.3M | Wed, Aug 19 |
| STRYKER RONDA EDirector | Sell | 3,274 | $1.1M | Wed, Aug 19 |
| STRYKER RONDA EDirector | Sell | 2,308 | $780.1K | Wed, Aug 19 |
| STRYKER RONDA EDirector | Sell | 805 | $276.5K | Wed, Aug 19 |
| STRYKER RONDA EDirector | Sell | 440 | $146.6K | Wed, Aug 19 |
| STRYKER RONDA EDirector | Sell | 320 | $107.8K | Wed, Aug 19 |
| STRYKER RONDA EDirector | Sell | 200 | $66.8K | Wed, Aug 19 |
| STRYKER RONDA EDirector | Sell | 80 | $26.8K | Wed, Aug 19 |
| Thomas H. Kean Jr | Sell | $8.0K | Wed, Jul 22 | Fri, Aug 7 |
| Alan Armstrong | Sell | $32.5K | Fri, Mar 27 | Tue, Jul 21 |
| Thomas H. Kean Jr | Sell | $8.0K | Tue, Jun 2 | Thu, Jun 18 |
Shares of medical technology company Stryker (NYSE:SYK) fell 4.2% in the morning session after the company reported third-quarter results marked by a 12.3% decline in net earnings and acknowledged that performance missed internal targets.
Stryker reported third quarter 2026 results with sales of US$6.52b and net income of US$753m, alongside a US$293m goodwill impairment and a cut to full year guidance.
Key TakeawaysStryker shares fell 5% after third-quarter sales and adjusted EPS missed estimates and it cut its 2026 guidance.
Stryker's (SYK) Q3 miss and lower guidance were anticipated, but its comments about underperformance
Stryker shares plunge 11.8% after Q3 earnings and sales miss estimates, prompting a 2026 outlook cut amid weak joint procedures and execution challenges.
CEO Kevin Lobo said the slowdown in hip and knee procedures is tied to broader economic concerns. The outgoing CEO also detailed the company’s decision to partner with CMR Surgical.
Stryker cuts its 2026 outlook amid weaker joint replacement demand and supply disruptions, despite MedSurg strength, margin gains and robotics investments.
Moby summary of Stryker Corporation's Q3 2026 earnings call
Stryker shares cratered 10% after a guidance cut that hit sales far harder than earnings, and a new CEO inherits the mess on his very first day. The real question is whether 2027 starts from a manageable reset or something far more troubling.
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.